Physician profile
Henry Mcconaha
NPI 1174260475
$820.26
in general payments reported to CMS, 2019-2025
20 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.77 · 2023: $81.46 · 2024: $242 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $89.57 | 2024-2025 | Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $85.03 | 2022-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $81.36 | 2024-2025 | |
| Grifols USA, LLC | $64.14 | 2022-2024 | Prolastin-C Liquid |
| Phathom Pharmaceuticals, INC. | $63.51 | 2025 | Voquezna |
| Exact Sciences Corporation | $35.94 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $34.26 | 2025 | Wegovy |
| Lilly USA, LLC | $28.81 | 2022-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $22.98 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $22.88 | 2025 | Auvelity |
| Alkermes, INC. | $22.05 | 2023 | Aristada, Lybalvi |
| Bioventus LLC | $21.00 | 2025 | Supartz Fx Sodium Hyaluronate |
| Novartis Pharmaceuticals Corporation | $20.65 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.50 | 2024 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $16.11 | 2025 | Korlym |
| Pfizer INC. | $15.78 | 2025 | |
| Merck Sharp & Dohme LLC | $15.59 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $14.37 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $13.28 | 2024 | Rexulti, Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Mcconaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.